You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 57 CD8+FoxP3+ cells represent early, effector T-cells and predict outcomes in patients with resectable non-small cell lung carcinoma (NSCLC) receiving neoadjuvant anti-PD-1-based therapy

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring and Novel Technologies
57 CD8+FoxP3+ cells represent early, effector T-cells and predict outcomes in patients with resectable non-small cell lung carcinoma (NSCLC) receiving neoadjuvant anti-PD-1-based therapy
Free

 

Online download statistics by month:

Online download statistics by month: November 2022 to March 2024

AbstractFullPdf
Nov 2022412033
Dec 2022144016
Jan 20237609
Feb 2023106011
Mar 202394016
Apr 2023112010
May 20236806
Jun 20238206
Jul 20234808
Aug 202360010
Sep 202394013
Oct 2023128011
Nov 2023104013
Dec 202316809
Jan 20247802
Feb 20246409
Mar 202494017
Total19320199